Name | 3-[(5S,8S,11S)-8-(4-aminobutyl)-5-(carboxymethylcarbamoyl)-16-nitro-7,10,13-trioxo-2-oxa-6,9,12-triazabicyclo[12.4.0]octadeca-1(14),15,17-trien-11-yl]propanoic acid |
---|---|
Synonyms |
d-3
unii-nmg938vj6t Tavilermide |
Description | Tavilermide is a selective, partial agonist of TrkA, or a nerve growth factor (NGF) mimetic. |
---|---|
Related Catalog | |
Target |
TrkA[1] |
In Vitro | Tavilermide (MIM-D3) is a tyrosine kinase TrkA receptor agonist, which can be used to treat dry eye.Tavilermide is a proteolytically stable, cyclic peptidomimetic that has been shown to be a partial TrkA receptor agonist. Tavilermide demonstrates activities similar to NGF (but does not bind to the p75NTR receptor) and can potentiate the effects of suboptimal concentrations of NGF[1]. |
References |
Molecular Formula | C24H32N6O11 |
---|---|
Molecular Weight | 580.54400 |
Exact Mass | 580.21300 |
PSA | 286.03000 |
LogP | 1.26590 |
Storage condition | 2-8℃ |